Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells
Multidrug resistance (MDR) to anticancer drugs remains a serious obstacle to the success of cancer chemotherapy. Resveratrol, a polyphenol, present in natural products exerts anticancer activity and acts as a potential MDR inhibitor in various drug-resistant cancer cells. In the process of resensiti...
Gespeichert in:
| Veröffentlicht in: | Nutrients 2022-02, Vol.14 (3), p.699 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 699 |
| container_title | Nutrients |
| container_volume | 14 |
| creator | Choi, Chul Yung Lim, Sung-Chul Lee, Tae-Bum Han, Song Iy |
| description | Multidrug resistance (MDR) to anticancer drugs remains a serious obstacle to the success of cancer chemotherapy. Resveratrol, a polyphenol, present in natural products exerts anticancer activity and acts as a potential MDR inhibitor in various drug-resistant cancer cells. In the process of resensitization of drug-resistant cancer cells, resveratrol has been shown to interfere with ABC transporters and drug-metabolizing enzymes, increase DNA damage, inhibit cell cycle progression, and induce apoptosis and autophagy, as well as prevent the induction of epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs). This review summarizes the mechanisms by which resveratrol counteracts MDR in acquired drug-resistant cancer cell lines and provides a critical basis for understanding the regulation of MDR as well as the development of MDR-inhibiting drugs. |
| doi_str_mv | 10.3390/nu14030699 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8838003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2627823210</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-124b9715e86826212a2fd6ececb2675e70070fa3f8f43c97f773b548547215703</originalsourceid><addsrcrecordid>eNpdkVtLAzEQhYMoKrUv_gBZ8EWE1Vx2k-yLoPUKiiD6akjTWU3ZJppsCvrr3aVVq_Myw8zH4QwHoV2Cjxir8LFLpMAM86paQ9sUC5pzXrD1lXkLDWOc4r4EFpxtoi1WUiFwKbfR851vwKRGh-xMRxszX2cPEOcQdBt8k9-4STIw6Xfgom3tp26tdz12at6TDd3tPKSXvANsbLVrs5F2BkI2gqaJO2ij1k2E4bIP0NPlxePoOr-9v7oZnd7mpsC8zQktxpUgJUguKaeEalpPOBgwY8pFCaK3XmtWy7pgphK1EGxcFrIsBCWlwGyATha6b2k8g4kB1wbdqLdgZzp8KK-t-ntx9lW9-LmSkkmMWSdwsBQI_j1BbNXMRtO9oB34FBXlTAoiaNWj-__QqU_Bde91FBWSMkp6R4cLygQfY4D6xwzBqk9O_SbXwXur9n_Q75zYFx9RkyQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627823210</pqid></control><display><type>article</type><title>Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Choi, Chul Yung ; Lim, Sung-Chul ; Lee, Tae-Bum ; Han, Song Iy</creator><creatorcontrib>Choi, Chul Yung ; Lim, Sung-Chul ; Lee, Tae-Bum ; Han, Song Iy</creatorcontrib><description>Multidrug resistance (MDR) to anticancer drugs remains a serious obstacle to the success of cancer chemotherapy. Resveratrol, a polyphenol, present in natural products exerts anticancer activity and acts as a potential MDR inhibitor in various drug-resistant cancer cells. In the process of resensitization of drug-resistant cancer cells, resveratrol has been shown to interfere with ABC transporters and drug-metabolizing enzymes, increase DNA damage, inhibit cell cycle progression, and induce apoptosis and autophagy, as well as prevent the induction of epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs). This review summarizes the mechanisms by which resveratrol counteracts MDR in acquired drug-resistant cancer cell lines and provides a critical basis for understanding the regulation of MDR as well as the development of MDR-inhibiting drugs.</description><identifier>ISSN: 2072-6643</identifier><identifier>EISSN: 2072-6643</identifier><identifier>DOI: 10.3390/nu14030699</identifier><identifier>PMID: 35277058</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>ABC transporters ; Antitumor activity ; Apoptosis ; Autophagy ; Bladder ; Breast cancer ; Cancer ; Cancer therapies ; Cell cycle ; Chemotherapy ; Colorectal cancer ; DNA damage ; Drug development ; Drug resistance ; Drug Resistance, Multiple ; Drug Resistance, Neoplasm ; Drugs ; Enzymes ; Epithelial-Mesenchymal Transition ; Glycoproteins ; Humans ; Kinases ; Leukemia ; Mesenchyme ; Metabolism ; Multidrug resistance ; Natural products ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Ovaries ; Polyphenols ; Prostate ; Protein expression ; Proteins ; Resveratrol ; Resveratrol - pharmacology ; Review ; Signal transduction ; Stem cells ; Tumor cell lines</subject><ispartof>Nutrients, 2022-02, Vol.14 (3), p.699</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-124b9715e86826212a2fd6ececb2675e70070fa3f8f43c97f773b548547215703</citedby><cites>FETCH-LOGICAL-c406t-124b9715e86826212a2fd6ececb2675e70070fa3f8f43c97f773b548547215703</cites><orcidid>0000-0003-4975-480X ; 0000-0001-6179-691X ; 0000-0002-2147-0170</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838003/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838003/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35277058$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choi, Chul Yung</creatorcontrib><creatorcontrib>Lim, Sung-Chul</creatorcontrib><creatorcontrib>Lee, Tae-Bum</creatorcontrib><creatorcontrib>Han, Song Iy</creatorcontrib><title>Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells</title><title>Nutrients</title><addtitle>Nutrients</addtitle><description>Multidrug resistance (MDR) to anticancer drugs remains a serious obstacle to the success of cancer chemotherapy. Resveratrol, a polyphenol, present in natural products exerts anticancer activity and acts as a potential MDR inhibitor in various drug-resistant cancer cells. In the process of resensitization of drug-resistant cancer cells, resveratrol has been shown to interfere with ABC transporters and drug-metabolizing enzymes, increase DNA damage, inhibit cell cycle progression, and induce apoptosis and autophagy, as well as prevent the induction of epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs). This review summarizes the mechanisms by which resveratrol counteracts MDR in acquired drug-resistant cancer cell lines and provides a critical basis for understanding the regulation of MDR as well as the development of MDR-inhibiting drugs.</description><subject>ABC transporters</subject><subject>Antitumor activity</subject><subject>Apoptosis</subject><subject>Autophagy</subject><subject>Bladder</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>DNA damage</subject><subject>Drug development</subject><subject>Drug resistance</subject><subject>Drug Resistance, Multiple</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drugs</subject><subject>Enzymes</subject><subject>Epithelial-Mesenchymal Transition</subject><subject>Glycoproteins</subject><subject>Humans</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Mesenchyme</subject><subject>Metabolism</subject><subject>Multidrug resistance</subject><subject>Natural products</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Ovaries</subject><subject>Polyphenols</subject><subject>Prostate</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>Resveratrol</subject><subject>Resveratrol - pharmacology</subject><subject>Review</subject><subject>Signal transduction</subject><subject>Stem cells</subject><subject>Tumor cell lines</subject><issn>2072-6643</issn><issn>2072-6643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkVtLAzEQhYMoKrUv_gBZ8EWE1Vx2k-yLoPUKiiD6akjTWU3ZJppsCvrr3aVVq_Myw8zH4QwHoV2Cjxir8LFLpMAM86paQ9sUC5pzXrD1lXkLDWOc4r4EFpxtoi1WUiFwKbfR851vwKRGh-xMRxszX2cPEOcQdBt8k9-4STIw6Xfgom3tp26tdz12at6TDd3tPKSXvANsbLVrs5F2BkI2gqaJO2ij1k2E4bIP0NPlxePoOr-9v7oZnd7mpsC8zQktxpUgJUguKaeEalpPOBgwY8pFCaK3XmtWy7pgphK1EGxcFrIsBCWlwGyATha6b2k8g4kB1wbdqLdgZzp8KK-t-ntx9lW9-LmSkkmMWSdwsBQI_j1BbNXMRtO9oB34FBXlTAoiaNWj-__QqU_Bde91FBWSMkp6R4cLygQfY4D6xwzBqk9O_SbXwXur9n_Q75zYFx9RkyQ</recordid><startdate>20220207</startdate><enddate>20220207</enddate><creator>Choi, Chul Yung</creator><creator>Lim, Sung-Chul</creator><creator>Lee, Tae-Bum</creator><creator>Han, Song Iy</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4975-480X</orcidid><orcidid>https://orcid.org/0000-0001-6179-691X</orcidid><orcidid>https://orcid.org/0000-0002-2147-0170</orcidid></search><sort><creationdate>20220207</creationdate><title>Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells</title><author>Choi, Chul Yung ; Lim, Sung-Chul ; Lee, Tae-Bum ; Han, Song Iy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-124b9715e86826212a2fd6ececb2675e70070fa3f8f43c97f773b548547215703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>ABC transporters</topic><topic>Antitumor activity</topic><topic>Apoptosis</topic><topic>Autophagy</topic><topic>Bladder</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>DNA damage</topic><topic>Drug development</topic><topic>Drug resistance</topic><topic>Drug Resistance, Multiple</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drugs</topic><topic>Enzymes</topic><topic>Epithelial-Mesenchymal Transition</topic><topic>Glycoproteins</topic><topic>Humans</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Mesenchyme</topic><topic>Metabolism</topic><topic>Multidrug resistance</topic><topic>Natural products</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Ovaries</topic><topic>Polyphenols</topic><topic>Prostate</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>Resveratrol</topic><topic>Resveratrol - pharmacology</topic><topic>Review</topic><topic>Signal transduction</topic><topic>Stem cells</topic><topic>Tumor cell lines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, Chul Yung</creatorcontrib><creatorcontrib>Lim, Sung-Chul</creatorcontrib><creatorcontrib>Lee, Tae-Bum</creatorcontrib><creatorcontrib>Han, Song Iy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nutrients</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, Chul Yung</au><au>Lim, Sung-Chul</au><au>Lee, Tae-Bum</au><au>Han, Song Iy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells</atitle><jtitle>Nutrients</jtitle><addtitle>Nutrients</addtitle><date>2022-02-07</date><risdate>2022</risdate><volume>14</volume><issue>3</issue><spage>699</spage><pages>699-</pages><issn>2072-6643</issn><eissn>2072-6643</eissn><abstract>Multidrug resistance (MDR) to anticancer drugs remains a serious obstacle to the success of cancer chemotherapy. Resveratrol, a polyphenol, present in natural products exerts anticancer activity and acts as a potential MDR inhibitor in various drug-resistant cancer cells. In the process of resensitization of drug-resistant cancer cells, resveratrol has been shown to interfere with ABC transporters and drug-metabolizing enzymes, increase DNA damage, inhibit cell cycle progression, and induce apoptosis and autophagy, as well as prevent the induction of epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs). This review summarizes the mechanisms by which resveratrol counteracts MDR in acquired drug-resistant cancer cell lines and provides a critical basis for understanding the regulation of MDR as well as the development of MDR-inhibiting drugs.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35277058</pmid><doi>10.3390/nu14030699</doi><orcidid>https://orcid.org/0000-0003-4975-480X</orcidid><orcidid>https://orcid.org/0000-0001-6179-691X</orcidid><orcidid>https://orcid.org/0000-0002-2147-0170</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6643 |
| ispartof | Nutrients, 2022-02, Vol.14 (3), p.699 |
| issn | 2072-6643 2072-6643 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8838003 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | ABC transporters Antitumor activity Apoptosis Autophagy Bladder Breast cancer Cancer Cancer therapies Cell cycle Chemotherapy Colorectal cancer DNA damage Drug development Drug resistance Drug Resistance, Multiple Drug Resistance, Neoplasm Drugs Enzymes Epithelial-Mesenchymal Transition Glycoproteins Humans Kinases Leukemia Mesenchyme Metabolism Multidrug resistance Natural products Neoplasms - drug therapy Neoplasms - metabolism Ovaries Polyphenols Prostate Protein expression Proteins Resveratrol Resveratrol - pharmacology Review Signal transduction Stem cells Tumor cell lines |
| title | Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T03%3A35%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20Basis%20of%20Resveratrol-Induced%20Resensitization%20of%20Acquired%20Drug-Resistant%20Cancer%20Cells&rft.jtitle=Nutrients&rft.au=Choi,%20Chul%20Yung&rft.date=2022-02-07&rft.volume=14&rft.issue=3&rft.spage=699&rft.pages=699-&rft.issn=2072-6643&rft.eissn=2072-6643&rft_id=info:doi/10.3390/nu14030699&rft_dat=%3Cproquest_pubme%3E2627823210%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627823210&rft_id=info:pmid/35277058&rfr_iscdi=true |